Table IV.
Multivariate analyses for OS, CSS and PFS.
| OS | CSS | PFS | ||||
|---|---|---|---|---|---|---|
| Parameter | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age at RNU years (continuous variable) | 1.025 (1.009-1.043) | 0.003 | 1.023 (1.005-1.040) | 0.011 | 1.015 (1.001-1.029) | 0.030 |
| Sex | ||||||
| Female vs. male | 0.627 (0.453-0.868) | 0.005 | 0.575 (0.408-0.810) | 0.002 | 0.729 (0.542-0.979) | 0.036 |
| Renal function | ||||||
| ≤60 vs. >60 ml/min/1.73 m2 | 1.109 (0.762-1.615) | 0.589 | 1.021 (0.691-1.508) | 0.918 | 0.934 (0.673-1.269) | 0.683 |
| HTN or DM | ||||||
| Yes vs. no | 1.374 (0.972-1.941) | 0.072 | 1.330 (0.927-1.909) | 0.121 | 1.302 (0.967-1.752) | 0.082 |
| Previous BC | ||||||
| Yes vs. no | 0.958 (0.602-1.525) | 0.905 | 0.889 (0.534-1.480) | 0.651 | 1.196 (0.811-1.765) | 0.367 |
| Concomitant BC | ||||||
| Yes vs. no | 1.024 (0.695-1.509) | 0.856 | 1.047 (0.699-1.570) | 0.823 | 1.131 (0.810-1.578) | 0.471 |
| Hydronephrosis | ||||||
| Present vs. absent | 0.824 (0.535-1.269) | 0.380 | 0.826 (0.524-1.302) | 0.410 | 0.784 (0.545-1.128) | 0.190 |
| Hematuria | ||||||
| Present vs. absent | 1.157 (0.703-1.902) | 0.567 | 1.126 (0.673-1.886) | 0.652 | 1.013 (0.661-1.552) | 0.954 |
| Tumor location | ||||||
| Ureter vs. renal pelvis | 1.694 (1.068-2.687) | 0.025 | 1.730 (1.065-2.809) | 0.027 | 1.588 (1.079-2.337) | 0.019 |
| Both vs. renal pelvis | 2.197 (1.462-3.302) | <0.001 | 2.170 (1.412-3.335) | <0.001 | 1.843 (1.290-2.632) | 0.001 |
| Pathological T stage | ||||||
| T2 vs. Tis/a/1 | 1.398 (0.777-2.516) | 0.263 | 3.194 (1.501-6.795) | 0.003 | 1.430 (0.994-2.409) | 0.179 |
| T3/4 vs. Tis/a/1 | 2.730 (1.667-4.469) | <0.001 | 6.209 (3.135-12.299) | <0.001 | 3.242 (2.111-4.979) | <0.001 |
| Lymph node stage | ||||||
| Nx vs. N0 | 0.907 (0.593-1.387) | 0.651 | 0.804 (0.520-1.244) | 0.327 | 1.079 (0.742-1.569) | 0.689 |
| N+ vs. N0 | 2.948 (1.656-5.246) | <0.001 | 2.803 (1.569-5.009) | 0.001 | 2.994 (1.801-4.997) | <0.001 |
| Tumor grade | ||||||
| High vs. low | 1.737 (0.521-5.793) | 0.369 | 4.355 (0.567-33.426) | 0.157 | 1.369 (0.423-4.429) | 0.600 |
| Tumor size | ||||||
| >2 vs. ≤2 cm | 1.218 (0.762-1.948) | 0.410 | 1.180 (0.711-1.959) | 0.453 | 1.429 (0.960-2.126) | 0.078 |
| Lymphovascular invasion | ||||||
| Present vs. absent | 1.798 (1.235-2.619) | 0.002 | 1.785 (1.208-2.638) | 0.004 | 1.933 (1.403-2.662) | <0.001 |
| Tumor necrosis | ||||||
| Present vs. absent | 1.321 (0.898-1.944) | 0.157 | 1.260 (0.841-1.89) | 0.263 | 1.089 (0.7776-1.527) | 0.622 |
| Adjuvant chemotherapy | ||||||
| Yes vs. no | 0.590 (0.330-1.056) | 0.076 | 0.545 (0.302-1.014) | 0.064 | 1.012 (0.957-1.577) | 0.957 |
| RDW-to-LYM% ratio | ||||||
| High (>0.80) vs. low (<0.80) | 2.046 (1.441-2.906) | <0.001 | 2.041 (1.415-2.945) | <0.001 | 1.502 (1.105-2.042) | 0.009 |
OS, overall survival; CSS, cancer-specific survival; PFS, progression-free survival; RNU, radical nephroureterectomy; eGFR, preoperative estimated glomerular filtration rate; HTN, hypertension; DM, diabetes mellitus; BC, bladder cancer; RDW-to-LYM% ratio, red cell distribution width to peripheral lymphocyte percentage ratio.